Together with its strategic partner, Janssen Pharmaceuticals Inc., AC Immune SA has recently announced the expansion of its Phase 1b/2a clinical trial evaluating ACI-35.030, a vaccine targeted at phosphorylated Tau proteins (pTau). AC Immune SA launched its clinical trial of ACI-35.030 in July 2019, aiming to recruit 32 participants with early Alzheimer's disease (AD) to evaluate the safety, tolerability and immunogenicity of the vaccine. As a vaccine candidate, ACI-35.030 has been designed to stimulate the generation of antibodies to pTau, which should bind to pathological Tau proteins in the brain and target them for clearance by the immune system. Recent results indicate that the treatment is well-tolerated, with no clinically-relevant safety concerns and eliciting a potent antibody response against pTau.AC Immune now plans to recruit additional participants to the second highest dose group, supporting continued development of ACI-35.030 into Phase 2b/3.
